Breakthrough in Gene-Edited Cell Therapy for Type 1 Diabetes
基因編輯細胞療法治療第一型糖尿病取得突破
Type 1 Diabetes (T1D) is a challenging autoimmune condition where the body attacks its own insulin-producing pancreatic cells.
第一型糖尿病（T1D）是一種具有挑戰性的自體免疫疾病，身體會攻擊自身產生胰島素的胰臟細胞。
For years, patients have relied on insulin injections to manage symptoms rather than address the root cause.
多年來，患者一直依賴胰島素注射來控制症狀，而非解決根本原因。
Now, a major breakthrough in gene-edited cell therapy offers hope for a functional cure.
如今，基因編輯細胞療法的一項重大突破為功能性治癒帶來了希望。
By utilizing CRISPR/Cas9 technology, researchers can transform stem cells into new beta cells and edit them to become "immune-evasive."
透過利用CRISPR/Cas9技術，研究人員可以將幹細胞轉化為新的β細胞，並進行編輯使其產生「免疫逃避」功能。
Leading firms like Vertex Pharmaceuticals and CRISPR Therapeutics are already conducting human clinical trials with promising early results.
像Vertex Pharmaceuticals和CRISPR Therapeutics等領先公司，已經在進行臨床人體試驗，並取得了令人期待的初步成果。
Scientists are focused on proving long-term safety and establishing efficient ways to scale this treatment so it can eventually reach millions of patients worldwide, marking a new era in regenerative medicine.
科學家們致力於證實其長期安全性，並建立有效的方法來擴大這種治療的規模，以便最終能惠及全球數百萬患者，標誌著再生醫學進入了新時代。
